Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neomycin sulfate + bacitracin zinc + lidocaine hydrochloride + polymyxin b is an over-the-counter topical combination drug composed of three first-aid antibiotics plus a local anesthetic. Bacitracin inhibits bacterial cell wall synthesis, polymyxin B disrupts bacterial membrane integrity, neomycin is an aminoglycoside that inhibits bacterial protein synthesis, and lidocaine provides local analgesia through blockade of voltage-gated sodium channels. The product is marketed by multiple manufacturers in cream or ointment formulations for prevention of infection and temporary pain relief in minor cuts, scrapes, and burns; branded examples include RECELLTIS and Biotic-Plus. The exact strengths and excipients vary by manufacturer, so this name refers to a formulation class defined by the same active-ingredient combination rather than one single sponsor-specific asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neomycin sulfate + bacitracin zinc + lidocaine hydrochloride + polymyxin b.